Here's what most people miss about Novo Nordisk's oral obesity drug deal: It's not just a new...

Here's what most people miss about Novo Nordisk's oral obesity drug deal: It's not just a new product, it's a delivery paradigm shift.

Injectables face adherence challenges. An oral GLP-1 could unlock massive market potential in India, where chronic disease management struggles.

Indian pharma: prepare for this shift in patient preference and market access. This is about true accessibility.

https://pharma.economictimes.indiatimes.com/news/pharma-industry/novo-nordisk-inks-2-1-bn-pact-with-vivtex-to-explore-oral-regimen-for-obesity-shots/128803481